PolyPeptide Group AG (XSWX:PPGN) Stock Based Compensation: CHF1.9 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:PPGN PolyPeptide Group AG XSWX:PPGN
76 GF Score
Price CHF43.75
GF Value CHF31.29
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is PolyPeptide Group AG Stock Based Compensation?

PolyPeptide Group AG XSWX:PPGN +4.79% 76 Stock Based Compensation is CHF1.9 Mil as of Dec. 2025. GuruFocus rates XSWX:PPGN with a GF Score™ of 76/100 and a GF Value™ of CHF31.29 (Significantly Overvalued). The stock has 6 warning signs investors should review.

PolyPeptide Group AG's Stock Based Compensation for the six months ended in Dec. 2025 was CHF1.0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was CHF1.9 Mil.

PolyPeptide Group AG Stock Based Compensation Related Terms

PolyPeptide Group AG Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for PolyPeptide Group AG's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PolyPeptide Group AG Stock Based Compensation Chart

PolyPeptide Group AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 1.26 1.14 0.79 1.12 1.89

PolyPeptide Group AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.72 0.42 0.90 0.99
XSWX:PPGN
76GF Score
PolyPeptide Group AG XSWX:PPGN
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PolyPeptide Group AG Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF1.9 Mil.

What does a Stock Based Compensation of CHF1.9 Mil mean?
PolyPeptide Group AG (XSWX:PPGN) has a Stock Based Compensation of CHF1.9 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for PolyPeptide Group AG and its competitors.
Is PolyPeptide Group AG's Stock Based Compensation too high?
PolyPeptide Group AG's current Stock Based Compensation is CHF1.9 Mil. Overall, PolyPeptide Group AG has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PolyPeptide Group AG's Stock Based Compensation compare to ZTS and UTHR?
PolyPeptide Group AG's Stock Based Compensation of CHF1.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for PolyPeptide Group AG and its competitors. PolyPeptide Group AG's current Stock Based Compensation is CHF1.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPeptide Group AG stock overvalued right now?
Based on GuruFocus' analysis, PolyPeptide Group AG (XSWX:PPGN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF31.29, compared to a current price of CHF43.75 — trading 39.8% above its estimated fair value. The current Stock Based Compensation is CHF1.9 Mil. PolyPeptide Group AG's overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For PolyPeptide Group AG (XSWX:PPGN), the current Stock Based Compensation is CHF1.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PolyPeptide Group AG (XSWX:PPGN) Overvalued in 2026?

Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued. The current stock price of CHF43.75 is trading 39.8% above its estimated GF Value™ of CHF31.29. GuruFocus considers PolyPeptide Group AG to be Significantly Overvalued.

Key valuation signals for XSWX:PPGN:

  • Stock Based Compensation: CHF1.9 Mil
  • GF Value™: CHF31.29 vs. price of CHF43.75 (39.8% above fair value)
  • GF Score™: 76/100 with 6 warning signs

No single metric tells the full story. See the XSWX:PPGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PolyPeptide Group AG Business Description

Address Neuhofstrasse 24, Baar, Zug, CHE, 6340
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
76GF Score

Get the complete analysis for XSWX:PPGN

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF43.75
Price
CHF31.29
GF Value